Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Steven Wagner
University of California, San Diego, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neurogenetic Pharmaceuticals, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Wagner is the co-founder and holds (b)(4) equity interest in Neurogenetic. The company holds worldwide exclusive rights to a platform of gramma-secretase modulators discovered by the company of which Dr. Wagner is one of the inventors. This project is to further optimize a unique set of soluble gamma-secretase modulators (SGSMs) to further explore novel Alzheimer’s Disease therapeutics. The ultimate goal of this project is to complete all of the necessary IND-enabling studies and to file an IND on a very potent and safe SGSM.
Optimization and preclinical development of soluble gamma-secretase modulators for AD
Alzheimer's disease (AD) is defined neuropathologically by extracellular plaques composed of ??amyloid (A?42) and intracellular tangles consisting of hyperphosphorylated forms of the microtubule?associated protein tau. A? accumulation and hyperphosphorylation of tau are recognized as key events leading to full blown AD neuropathology. The ultimate goal of this project is to complete all of the necessary IND?enabling studies and to file an IND on a very potent and safe soluble gamma?secretase modulator (SGSM) for Alzheimer's disease.
Filed on July 15, 2016.
Tell us what you know about Steven Wagner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Steven Wagner”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Steven Wagner | University of California, San Diego | Conflict of Interest | Neurogenetic Pharmaceuticals, Inc | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.